Obesity is associated with eye diseases, but the underlying structural changes and pathogenic mechanisms have not been examined in detail. Here, we assessed the effects of morbid obesity on the morphometric indices of eye disease. Methods: Morbidly obese volunteers (n=101, body mass index [BMI] ≥40) and healthy individuals (n=95, BMI: 18.50-24.99) were examined by Goldman applanation tonometry, pachymetry, and spectral domain optical coherence tomography. Intraocular pressure, anterior chamber depth, axial length, central corneal thickness, retinal nerve fiber layer thickness, central foveal thickness, and choroidal thickness were compared between groups. Results: Uncorrected intraocular pressure was significantly greater in the morbidly obese group than in the healthy control group (15.5 ± 2.5 vs. 14.5 ± 2.6 mmHg, p=0.009), whereas axial length, anterior chamber depth, and central corneal thickness did not differ between the groups. The mean retinal nerve fiber layer thickness at the temporal quadrant was reduced in the morbidly obese group (72.7 ± 13.6 vs. 85.05 ± 52.6 μm, p=0.024). Similarly, the mean retinal thicknesses at nasal and temporal 1500-μm locations were lower in the morbidly obese group (346.6 ± 18.2 vs. 353.7 ± 18.8 μm, p=0.008; 323.1 ± 20.3 vs. 330.0 ± 18.9 μm, p=0.001). The mean choroidal thickness was also reduced in almost all measurement locations (fovea, temporal 500 and 1000 μm, and nasal 500, 1000, and 1500 μm) of the obese group (p<0.05). Weight and BMI were negatively correlated with subfoveal choroidal thickness (r=-0.186, p=0.009; r=-0.173, p=0.015). Conclusion: Morbid obesity is associated with elevated uncorrected intraocular pressure and signs of neuropathy and retinopathy. Obesity may thus increase the risks of glaucoma and glaucomatous optic neuropathy.

The photorefractometer method was beneficial in the measurement of refractive errors of school-aged children. The PlusoptiX A12 photorefractometer method may eliminate the need for cycloplegia in the detection of refractive errors in children. [J Pediatr Ophthalmol Strabismus. 2018;55(5):306-311.].

Objective:To evaluate the intraocular pressure (IOP), central corneal thickness (CCT), and peripapillary retinal nerve fiber layer (RNFL) thickness in Patients with Obstructive Sleep Apnea Syndrome.Methods:In this prospective study, 103 patients with OSAS (study group) and 37 healthy subjects were enrolled. All participants underwent comprehensive ophthalmic examinations. Mean outcome measures were intraocular pressure by Goldmann applanation tonometry, CCT measurement using ultrasound pachymeter and peripapillary RNFL thickness measured by spectral-domain optical coherence tomography.Results:The differences between the mean values of RNFL thickness in all quadrants were similar in both groups and were not statistically significant (p=0.274). The IOP and CCT measurement averages of all patients with OSAS were lower than the control group. However, this difference was not statistically significant. There was no correlation between the apnea-hypopnea index, lowest oxygen saturation (LAST) or Body Mass Index (BMI) and the peripapillary RNFL thickness, IOP or CCT when OSAS group was divided by severity.Conclusions:The study results suggest that peripapillary RNFL thickness, IOP or CCT did not differ significantly between OSAS and control groups. We also found no correlation between apnea severity (AHI), lowest oxygen saturation (LAST) and BMI and RNFL, CCT and IOP.

Purpose To investigate the effects of subconjunctival bevacizumab, ranibizumab, and aflibercept in an experimental corneal neovascularization model. Materials and methods The eyes of 24 rats were chemically cauterized and randomly divided into four groups: bevacizumab group (0.05 mL/1.25 mg bevacizumab), ranibizumab group (0.05 mL/0.5 mg ranibizumab), aflibercept group (0.05 mL/1.25 mg aflibercept), and control group (0.05 mL saline solution). Plasma vascular endothelial growth factor (VEGF) levels were among the major measurement outcomes to assess corneal neovascularization. The collected plasmas were analyzed using the SIGMA RAB0511 Rat VEGF Elisa kit. The PCR technique and VEGF amplification procedures were used for molecular analysis. Each cornea was removed and histologically examined on day 21. Corneal images were evaluated by image analyzer software. Results In the post-injection period, the number of major corneal arteries decreased significantly in the injection groups when compared to the control group ( p = 0.037), but no statistically significant differences were noted among the injection groups ( p > 0.05). The aflibercept group had the lowest area of neovascularization. Immunohistochemical staining revealed substantially lower VEGF percentages in neovascularized arteries of the injection groups than the control group ( p = 0.015). In TUNEL staining, the mean TUNEL value (number/1hpf) was substantially greater in the control group than in the injection groups, but the mean TUNEL values were similar between the injection groups ( p = 0.019, p > 0.05, respectively). No statistically significant differences were observed between the groups in terms of corneal surface area with increased cellularity, edema, and inflammation ( p = 0.263). The mean plasma VEGF concentration in the control group was statistically greater than those in the injection groups ( p = 0.001). Conclusion Subconjunctival bevacizumab, ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting corneal neovascularization without causing epitheliopathy in an experimental rat model compared to the controls. However, no significant results were noted between these three anti-VEGF molecules.

2016/112.